The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Intermittent chemotherapy (ICh) for metastatic castration-resistant prostate cancer (mCRPC): Results of a prospective randomized phase II trial of the DoD Prostate Cancer Clinical Trials Consortium.
Andrea Lynne Harzstark
No relevant relationships to disclose
Tomasz M. Beer
No relevant relationships to disclose
Vivian K. Weinberg
No relevant relationships to disclose
Celestia S. Higano
No relevant relationships to disclose
Luke T. Nordquist
No relevant relationships to disclose
Jonathan E. Rosenberg
No relevant relationships to disclose
Joshi J. Alumkal
No relevant relationships to disclose
Evan Y. Yu
No relevant relationships to disclose
Joanna Mi
No relevant relationships to disclose
Eric Jay Small
No relevant relationships to disclose